EW · NYSE · STOCK
Edwards Lifesciences (EW) Stock Analysis
$90.23
52W $72.30 – $96.29
59/100
$52.11B
52.0
0.85
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is EW Bullish or Bearish?
Bullish.
Innellis AI committee rates Edwards Lifesciences (EW) Buy with a composite score of 59/100
, based on 6 analysts with 67% agreement.
Last updated August 25, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +16.38 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -3.62 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The primary driver is low leverage (debt-to-equity 0.06) -- balance sheet can absorb a shock. The main limiting factor is p/e of 53.5 is expensive by classic value standards. The committee is constructive but not yet at full conviction.
Bull & Bear Case
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.06) -- balance sheet can absorb a shock — Risk
- News sentiment is positive (+0.40 across 17 articles, 14d) — News
Bear Case
- P/E of 53.5 is expensive by classic value standards — Value
- Price-to-book of 4.8x prices in significant intangible value — Value
- EPS declining -75.2% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 25, 2026
Overall Committee Score
59/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 46%
of 192 Healthcare peers
Value Analyst
bearish
40
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 53.5 is expensive by classic value standards
Growth Analyst
bearish
40
/ 100 · High confidence
Growth story is weak, decelerating, or inconsistent
− EPS declining -75.2% YoY despite any revenue growth
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
bullish
75
/ 100 · Moderate confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.06) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
70
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.40 across 17 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3063.01)
Investment Thesis Evolution
Committee score moved marginally from 58.6 to 58.6.
Comparing 2026-08-24 to 2026-08-25 (1 day apart).
Technical Analysis
RSI (14)
51.0
Neutral
MACD Histogram
-0.079
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Support
$85.58
Resistance
$91.92
Bollinger %B
0.57
Inside Bands
Price vs Moving Averages
EMA 9
$90.68
Below
EMA 21
$89.99
Above
EMA 50
$88.66
Above
EMA 200
$84.55
Above
Fundamental Analysis
Valuation
49
Growth
60
Profitability
77
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
52.0×
P/B Ratio
4.91×
PEG Ratio
-0.69
Dividend Yield
0.00%
52W High
$96.29
52W Low
$72.30
Quality & Growth
ROE
1038.4%
ROA
783.7%
Gross Margin
7798.0%
Operating Margin
2809.4%
Revenue Growth YoY
—
Debt / Equity
0.07
AI Fundamental Assessment
P/E ratio of 52.0 (rich relative to a 15-40x range); Price-to-book of 4.9x; PEG ratio of -0.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 10.4%; Return on assets of 7.8%; Net margin of 15.4%; Gross margin of 78.0%; Current ratio of 4.52 (healthy short-term liquidity); Debt-to-equity of 0.07; Free cash flow per share is positive (2.49); Most recent quarter beat estimates by 2.3%; 2 consecutive earnings beats; EPS growth decelerating (+34.5% -> +0.0% QoQ); Average YoY EPS growth of 16.4%; Analyst estimates rising over recent quarters
Get the Full EW Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →